Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (81-90 of 177) with videos related to

Pageof 18
Sort By:
Journal of Medical Economics|December 21, 2019
Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costsAxel Dignass, John Waller, Joseph C Cappelleri, et al.
United European Gastroenterology Journal|May 4, 2023
Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort studyBélène Podmore, Dominik Beier, Johan Burisch, et al.
The American Journal of Gastroenterology|July 12, 2023
Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future DirectionsMarla Dubinsky, Alison Potts Bleakman, Remo Panaccione, et al.
United European Gastroenterology Journal|May 11, 2024
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast studyFerdinando D'Amico, Fernando Gomollón, Giorgos Bamias, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 26, 2023
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory DiseaseUlf Müller-Ladner, Axel Dignass, Karl Gaffney, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 25, 2017
Cost-utility of biological treatment sequences for luminal Crohn's disease in EuropeFanni Rencz, László Gulácsi, Márta Péntek, et al.
The Lancet. Gastroenterology & Hepatology|April 9, 2022
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD surveyTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Journal of Crohn'S & Colitis|August 30, 2024
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III TrialsRemo Panaccione, Christopher Ma, Vipul Jairath, et al.
Journal of Crohn'S & Colitis|June 13, 2024
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT ProgrammeSilvio Danese, Axel Dignass, Katsuyoshi Matsuoka, et al.
Journal of Crohn'S & Colitis|January 29, 2016
Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim ResultsAxel Dignass, Ayesha Akbar, Ailsa Hart, et al.
Pageof 18

Showing results (81-90 of 177) with videos related to

Sort By:
Pageof 18
Journal of Medical Economics|December 21, 2019
Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costsAxel Dignass, John Waller, Joseph C Cappelleri, et al.
United European Gastroenterology Journal|May 4, 2023
Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort studyBélène Podmore, Dominik Beier, Johan Burisch, et al.
The American Journal of Gastroenterology|July 12, 2023
Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future DirectionsMarla Dubinsky, Alison Potts Bleakman, Remo Panaccione, et al.
United European Gastroenterology Journal|May 11, 2024
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast studyFerdinando D'Amico, Fernando Gomollón, Giorgos Bamias, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 26, 2023
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory DiseaseUlf Müller-Ladner, Axel Dignass, Karl Gaffney, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 25, 2017
Cost-utility of biological treatment sequences for luminal Crohn's disease in EuropeFanni Rencz, László Gulácsi, Márta Péntek, et al.
The Lancet. Gastroenterology & Hepatology|April 9, 2022
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD surveyTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Journal of Crohn'S & Colitis|August 30, 2024
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III TrialsRemo Panaccione, Christopher Ma, Vipul Jairath, et al.
Journal of Crohn'S & Colitis|June 13, 2024
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT ProgrammeSilvio Danese, Axel Dignass, Katsuyoshi Matsuoka, et al.
Journal of Crohn'S & Colitis|January 29, 2016
Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim ResultsAxel Dignass, Ayesha Akbar, Ailsa Hart, et al.
Pageof 18